{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:09:06Z","timestamp":1793862546532,"version":"4.6.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["EP\/P020267\/1"],"award-info":[{"award-number":["EP\/P020267\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000848","name":"University of Edinburgh","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000848","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill &amp; Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-001754"],"award-info":[{"award-number":["INV-001754"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.vaccine.2024.01.072","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T06:37:07Z","timestamp":1706855827000},"page":"1311-1318","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Modelling the health and economic impacts of M72\/AS01E vaccination and BCG-revaccination: Estimates for South Africa"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9305-534X","authenticated-orcid":false,"given":"Tom","family":"Sumner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8923-0301","authenticated-orcid":false,"given":"Rebecca A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4191-0361","authenticated-orcid":false,"given":"Christinah","family":"Mukandavire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8467-1324","authenticated-orcid":false,"given":"Allison","family":"Portnoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chathika K.","family":"Weerasuriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1958-0944","authenticated-orcid":false,"given":"Roel","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Scarponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3491-1809","authenticated-orcid":false,"given":"Mark","family":"Hatherill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas A.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.01.072_b0005","unstructured":"World Health Organisation. Global Tuberculosis Report. 2022 [accessed 2021; Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/363752."},{"key":"10.1016\/j.vaccine.2024.01.072_b0010","unstructured":"United Nations Department of Economic and Social Affairs, S.D. Sustainable Development Goals. 2023 [accessed 2023; Available from: https:\/\/sdgs.un.org\/goals."},{"issue":"6","key":"10.1016\/j.vaccine.2024.01.072_b0015","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/joim.13197","article-title":"New tuberculosis vaccines: advances in clinical development and modelling","volume":"288","author":"Weerasuriya","year":"2020","journal-title":"J Intern Med"},{"issue":"564","key":"10.1016\/j.vaccine.2024.01.072_b0020","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax4607","article-title":"Potential impact of tuberculosis vaccines in China, South Africa, and India","volume":"12","author":"Harris","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2024.01.072_b0025","unstructured":"Stop TB Partnership Working Group on New TB Vaccines. TB Vaccine Pipeline. 05\/06\/2023]; Available from: https:\/\/newtbvaccines.org\/tb-vaccine-pipeline\/."},{"issue":"25","key":"10.1016\/j.vaccine.2024.01.072_b0030","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of M72\/AS01(E) vaccine to prevent tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.072_b0035","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis Infection with H4: IC31 Vaccine or BCG Revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2024.01.072_b0040","article-title":"New tuberculosis vaccines in India: Modelling the potential health and economic impacts of adolescent\/adult vaccination with M72\/AS01 (E) and BCG-revaccination","author":"Clark","year":"2023","journal-title":"medRxiv"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.072_b0045","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/s41467-022-28234-7","article-title":"Cost-effectiveness of routine adolescent vaccination with an M72\/AS01(E)-like tuberculosis vaccine in South Africa and India","volume":"13","author":"Harris","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.072_b0050","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41541-022-00554-1","article-title":"Feasibility of novel adult tuberculosis vaccination in South Africa: a cost-effectiveness and budget impact analysis","volume":"7","author":"Jayawardana","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2024.01.072_b0055","unstructured":"United Nations Department of Economic and Social Affairs, P.D. World Population Projections (2019 revision). 2019; Available from: https:\/\/population.un.org\/wpp\/Download\/Standard\/Population\/."},{"issue":"8","key":"10.1016\/j.vaccine.2024.01.072_b0060","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S1473-3099(22)00149-9","article-title":"Prevalence of bacteriologically confirmed pulmonary tuberculosis in South Africa, 2017\u201319: a multistage, cluster-based, cross-sectional survey","volume":"22","author":"Moyo","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.01.072_b0065","unstructured":"Joint United Nations Programme on HIV\/AIDS, UNAIDS DATA 2020. 2020: Geneva."},{"issue":"4","key":"10.1016\/j.vaccine.2024.01.072_b0070","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1016\/S2214-109X(23)00045-1","article-title":"The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study","volume":"11","author":"Clark","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2024.01.072_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.epidem.2023.100678","article-title":"Demonstrating multi-country calibration of a tuberculosis model using new history matching and emulation package - hmer","volume":"43","author":"Scarponi","year":"2023","journal-title":"Epidemics"},{"key":"10.1016\/j.vaccine.2024.01.072_b0080","doi-asserted-by":"crossref","unstructured":"Iskauskas, A., hmer: History Matching and Emulation package. 2022.","DOI":"10.32614\/CRAN.package.hmer"},{"issue":"4","key":"10.1016\/j.vaccine.2024.01.072_b0085","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/tmi.13038","article-title":"Socio-economic gradients in prevalent tuberculosis in Zambia and the Western Cape of South Africa","volume":"23","author":"Yates","year":"2018","journal-title":"Trop Med Int Health"},{"issue":"2","key":"10.1016\/j.vaccine.2024.01.072_b0090","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.socscimed.2007.08.026","article-title":"The social epidemiology of tuberculosis in South Africa: a multilevel analysis","volume":"66","author":"Harling","year":"2008","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.vaccine.2024.01.072_b0095","unstructured":"UN AIDS, HIV estimates with uncertianty bounds 1990-2020. 2021."},{"key":"10.1016\/j.vaccine.2024.01.072_b0100","unstructured":"World Health Organisation. WHO preferred product characteristics for new tuberculosis vaccines. 2018; Available from: http:\/\/apps.who.int\/iris\/handle\/10665\/273089."},{"issue":"32","key":"10.1016\/j.vaccine.2024.01.072_b0105","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.vaccine.2015.05.088","article-title":"Safety and immunogenicity of candidate vaccine M72\/AS01E in adolescents in a TB endemic setting","volume":"33","author":"Penn-Nicholson","year":"2015","journal-title":"Vaccine"},{"issue":"45","key":"10.1016\/j.vaccine.2024.01.072_b0110","doi-asserted-by":"crossref","first-page":"e13120","DOI":"10.1097\/MD.0000000000013120","article-title":"Long-term safety and immunogenicity of the M72\/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial","volume":"97","author":"Kumarasamy","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"21","key":"10.1016\/j.vaccine.2024.01.072_b0115","first-page":"193","article-title":"Revised BCG vaccination guidelines for infants at risk for HIV infection","volume":"82","author":"World Health Organisation","year":"2007","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2024.01.072_b0120","unstructured":"UNICEF. Bacillus Calmette\u2013Gu\u00e9rin (BCG) vaccine price data. 2021; Available from: https:\/\/www.unicef.org\/supply\/documents\/bacillus-calmettegu%C3%A9rin-bcg-vaccine-price-data."},{"key":"10.1016\/j.vaccine.2024.01.072_b0125","unstructured":"Gavi The Vaccine Alliance. GAVI Alliance Vaccine Introduction Grant and Operational Support for Campaigns Policy. Version 1.0. 2013; Available from: www.gavi.org."},{"key":"10.1016\/j.vaccine.2024.01.072_b0130","unstructured":"UNICEF. Costs of vaccinating a child. 2020; Available from: https:\/\/immunizationeconomics.org\/recent-activity\/2021\/6\/15\/standard-costs-of-vaccinating-a-child."},{"issue":"24","key":"10.1016\/j.vaccine.2024.01.072_b0135","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1016\/j.vaccine.2018.03.009","article-title":"BCG vaccine: WHO position paper, February 2018 \u2013 Recommendations","volume":"36","author":"World Health","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.01.072_b0140","unstructured":"GBD 2019 Disease and Injuries Collaborators, Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet, 2020. 396(10258): p. 1204-1222."},{"key":"10.1016\/j.vaccine.2024.01.072_b0145","unstructured":"The World Bank. World development indicators. 2022; Available from: https:\/\/data.worldbank.org\/."},{"issue":"6","key":"10.1016\/j.vaccine.2024.01.072_b0150","doi-asserted-by":"crossref","first-page":"e000964","DOI":"10.1136\/bmjgh-2018-000964","article-title":"Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data","volume":"3","author":"Ochalek","year":"2018","journal-title":"BMJ Glob Health"},{"issue":"1","key":"10.1016\/j.vaccine.2024.01.072_b0155","doi-asserted-by":"crossref","first-page":"e1004155","DOI":"10.1371\/journal.pmed.1004155","article-title":"The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: a modeling study","volume":"20","author":"Portnoy","year":"2023","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2024.01.072_b0160","doi-asserted-by":"crossref","unstructured":"Scarponi, D., et al., Is neglect of self-clearance biassing TB vaccine impact estimates? medRxiv, 2023.","DOI":"10.1101\/2023.04.11.23288400"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24000963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24000963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:35:01Z","timestamp":1759404901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24000963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0264410X24000963"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.072","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modelling the health and economic impacts ofM72\/AS01E vaccination and BCG-revaccination: Estimates for South Africa","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}